Amino Science Labs sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration. Full disclaimer.
🔥 FREE SHIPPING ON ORDERS OVER $250 🔥
Research Peptide
Buy 1 Get 1 FREE!
On select sizes — each card shows the vials you get and what you pay.
Fast shipping
Same-day dispatch
Third-party tested
U.S. accredited labs
99%+ purity
HPLC verified
3x
TRIPLE AGONIST
GLP-1, GIP, and glucagon receptors
24%
BODY WEIGHT
Reduction in Phase 2 trials (retatrutide)
50+
PUBLICATIONS
Rapidly growing research base
2023
PHASE 2 DATA
Presented at ADA conference
39AA
SEQUENCE
Modified triple-agonist peptide
Free shipping
on orders over $150
Quality guarantee
99%+ purity verified
Secure checkout
256-bit SSL encryption
Research
GLP-3 R (CAS 2381089-83-2) is the research designation applied to the synthetic triple-receptor agonist peptide also catalogued as retatrutide / LY3437943. It corresponds to the molecular formula C221H342N46O68 and a monomeric mass of approximately 4731 Da. Unlike single- or dual-incretin analogs, this 39-residue peptide was engineered to engage three class B G-protein-coupled receptors within receptor-expressing cell systems: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Because of this three-way pharmacology, laboratories frequently describe it as a triagonist scaffold. This material is supplied strictly as a reference compound for in-vitro and preclinical laboratory investigation and is not intended for human or veterinary use.
The GLP-3 R sequence is built on a GIP-derived backbone that has been modified at several positions to alter its biochemical behavior in vitro. Structural elements characterized in the peptide-chemistry literature include:
In published in-vitro pharmacology, this scaffold has been profiled for cyclic-AMP accumulation across cells recombinantly expressing human GIPR, GLP-1R, and GCGR, with reported half-maximal effective concentrations in the sub-nanomolar to low-nanomolar range (approximately 0.06 nM at GIPR, 0.78 nM at GLP-1R, and 5.8 nM at GCGR). This balanced-yet-differential potency profile is the primary characteristic that distinguishes it from mono- and dual-agonist reference peptides in comparative receptor panels. Reported preclinical rodent studies have employed diet-induced-obese and GLP-1R knockout mouse models together with indirect calorimetry and pair-feeding designs as experimental tools to examine how the three receptor pathways contribute to measured signaling readouts, and cell and tissue systems have been used to probe hepatic lipid handling at the biochemical level. All such work is described here only to summarize the published research literature; it remains preliminary and ongoing, and no health, therapeutic, or performance claims are made or implied.
Each research lot of GLP-3 R is specified at greater than or equal to 99% purity. Identity and purity are established using orthogonal analytical methods common to peptide reference materials:
As a lyophilized peptide reference material, GLP-3 R is subject to standard laboratory handling and storage practices for research chemicals. This handling guidance pertains solely to preserving analytical integrity in the laboratory and does not imply any route of administration.
For laboratory research use only. Content here summarizes what has been studied about this material and its analytical characterization; it is not medical advice and makes no diagnostic, therapeutic, or human-use claims.
GLP-3 R is a supplier shorthand for the triple-receptor agonist peptide identified by CAS 2381089-83-2 (also known as retatrutide / LY3437943), formula C221H342N46O68. The name reflects its studied activity across three receptors — GIPR, GLP-1R, and GCGR — rather than a distinct fourth incretin receptor. It is offered solely as an in-vitro research reference material.
In receptor-expressing cell assays, the peptide has been reported to activate the GIP receptor, the GLP-1 receptor, and the glucagon receptor and to stimulate downstream cyclic-AMP signaling at each. This multi-receptor profile is why comparative in-vitro studies group it separately from single-target (GLP-1R only) or dual-target reference peptides.
Lots are characterized by reversed-phase HPLC for main-peak purity (specified at greater than or equal to 99%) and by mass spectrometry (ESI-MS or MALDI-TOF) to confirm the observed mass matches the theoretical ~4731 Da from the molecular formula. A batch-specific Certificate of Analysis reports these results along with net peptide content.
The GIP-based backbone carries non-coded Aib residues at positions 2 and 20 (studied for DPP-4 resistance), an alpha-methyl-leucine modification near position 13, and a C20 fatty-diacid group attached via a gamma-glutamate/AEEA linker that has been examined for albumin binding and extended in-vitro half-life. The C-terminus is amidated.
Published preclinical work has used diet-induced-obese and GLP-1R knockout rodent models alongside indirect calorimetry and pair-feeding designs as experimental tools to study how the three receptor pathways relate to measured signaling readouts, plus cell and tissue systems probing hepatic lipid handling. These are descriptions of the research literature only and are preliminary; they are not health claims.
This product is sold strictly for in-vitro research and laboratory use only. It is not intended for human or animal consumption, diagnostic purposes, or therapeutic application.
By purchasing this product, you confirm that you are a qualified researcher operating within an appropriate laboratory environment and will use this compound in accordance with all applicable local, state, and federal regulations.
Amino Science Labs assumes no liability for misuse of this product outside of its intended research application.
As a lyophilized peptide reference material, it should be handled using standard laboratory practices for research chemicals — appropriate PPE, protection from moisture and light, and cold storage per the Certificate of Analysis to preserve analytical integrity. This guidance concerns laboratory sample stability only and does not describe or imply any human or animal use.
No. This material is supplied exclusively for laboratory research and in-vitro/preclinical experimentation. It is not a drug, supplement, or food, and nothing here should be interpreted as medical guidance or as endorsing human or veterinary administration. Standard laboratory handling and storage practices apply.
